Oncimmune Holdings ( (GB:ONC) ) has shared an announcement.
Oncimmune Holdings plc announced the appointment of Simon Bonney and James Varney as joint administrators by IPF Invest Co 2 S.A.R.L. This development led to the resignation of Cavendish Capital Markets Limited as the company’s Nominated Adviser and Joint Broker, with Zeus Capital Limited also resigning as Joint Broker. The company has no plans to appoint a replacement Nominated Adviser, which could result in the cancellation of its shares’ admission to trading on AIM if not addressed within a month. Stakeholders and potential asset acquirers are advised to contact the joint administrators.
More about Oncimmune Holdings
Oncimmune Holdings is a precision medicine company that specializes in analyzing immune interactions through autoantibody profiles. The company partners with global pharmaceutical and biotech companies, as well as contract research organizations, to discover novel biomarkers for developing targeted therapies for immune-mediated diseases. Oncimmune operates with a scientific team and technology platform to aid drug discovery and development, with headquarters in the UK and facilities in Germany, the US, and Europe.
YTD Price Performance: -92.06%
Average Trading Volume: 437,642
Technical Sentiment Signal: Buy
Current Market Cap: £1.27M
See more data about ONC stock on TipRanks’ Stock Analysis page.